Publications scientifiques
Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).
-
Pneumopathies interstitielles diffuses (PID)
The Interstitial Lung Disease Patient Pathway: From Referral to Diagnosis
ERJ Open Research 11, nᵒ 2 (mars 2025): 00899‑02024
-
Pneumopathies interstitielles diffuses (PID)
Protocol and Research Program of the European Registry and Biobank for Interstitial Lung Diseases (eurILDreg)
BMC Pulmonary Medicine 24, nᵒ 1 (novembre 2024): 572.
-
Pneumopathies interstitielles diffuses (PID)
European ILD Registry Algorithm for Self-Assessment in Interstitial Lung Diseases (eurILDreg ASA-ILD)
PLOS ONE 20, nᵒ 1 (janvier 2025): e0316484.
-
Pneumopathies interstitielles diffuses (PID)
RPA3-UMAD1 Rs12702634 and Rheumatoid Arthritis-Associated Interstitial Lung Disease in European Ancestry
Rheumatology Advances in Practice 8, nᵒ 2 (juin 2024): rkae059.
-
Pneumopathies interstitielles diffuses (PID)
Admission Chest CT Scan of Intensive Care Patients with Interstitial Lung Disease: Unveiling Its Limited Predictive Value through Visual and Automated Analyses in a Retrospective Study (ILDICTO)
Respiratory Medicine and Research 86 (novembre 2024): 101140.
-
Pneumopathies interstitielles diffuses (PID)
Automated AI-based image analysis for quantification and prediction of interstitial lung disease in systemic sclerosis patients
Respiratory Research 26, nᵒ 1 (janvier 2025): 39
-
Pneumopathies interstitielles diffuses (PID)
Vasodilator Drugs and Heart-Related Outcomes in Systemic Sclerosis: An Exploratory Analysis
RMD Open 10, nᵒ 4 (décembre 2024): e004918.
-
Pneumopathies interstitielles diffuses (PID)
Heart and systemic sclerosis—findings from a national cohort study
Rheumatology 63, nᵒ 12 (décembre 2024): 3380‑89.
-
Pneumopathies interstitielles diffuses (PID)
Evaluation of efficacy and safety of rituximab in patients with progressive interstitial lung disease (ILD) with inflammatory component (EvER-ILD2): A multicentre double-blind placebo-controlled randomized trial
Respiratory Medicine and Research 87 (novembre 2024): 101144.
-
Pneumopathies interstitielles diffuses (PID)
Long-Term Functional Course of Sjögren’s Disease-Associated Interstitial Lung Disease
ERJ Open Research 10, nᵒ 5 (octobre 2024).